Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Auteur de référence en rhumatologie
22 articles scientifiques publiés — un praticien à la pointe de la recherche
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis and rheumatism · 2005
AbstractObjectiveChildhood dermatomyositis (DM) is often a chronic disease, lasting many years. It has traditionally been treated with long‐term corticosteroid therapy; side effects are often seen. For more than a decade, methotrexate (MTX) has been safely used for the treatment of juvenile arthritis. Here, we report use of MTX as first‐line therapy for DM, along with aggressively tapered corticosteroids, in an attempt to reduce treatment‐related side effects.MethodsWe studied an inception cohort of 31 children with DM who were rigorously followed up in our myositis clinic, and compared them with a control group of 22 patients with incident cases of juvenile DM who received treatment just before we instituted a policy of first‐line therapy with MTX. The mean starting dosage of MTX in the study group was 15 mg/m2/week.ResultsBoth groups had similar improvement in strength and physical function; however, the median time during which patients in the study group received corticosteroids was 10 months, compared with 27 months for controls (P < 0.0001). As a result, the cumulative prednisone dose in the study group was approximately half that in the control group (7,574 mg versus 15,152 mg; P = 0.0006). The study group had greater height velocity during the first year of treatment and a smaller increase in the body mass index over the first 2 years. In the control group, the relative risk of cataracts developing was 1.95 (95% confidence interval 1.05–4.17). Side effects of MTX were rarely observed.ConclusionUse of MTX in conjunction with an aggressively tapered course of prednisone may be as effective as traditional long‐term corticosteroid therapy for children with DM, while decreasing the cumulative dose of corticosteroids.
The International journal of oral & maxillofacial implants · 2016
Journal of community health · 2010
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Best practice & research. Clinical rheumatology · 2026 · Journal Article
Ibrahim M, He E, Tran D, Vundamati D, et al.
Nanomedicine : nanotechnology, biology, and medicine · 2026 · Journal Article
Wei X, Zhao G, Xu X, Jia Z, et al.
Nanoscale advances · 2025 · Journal Article
Nguyen LM, Wang Y, Quynh Vu GT, Hoai Ta QT, et al.
Journal of bone and mineral metabolism · 2025 · Journal Article
Nguyen AT, Bui TT, Tran NTM, Nguyen ON, et al.
Nanomedicine : nanotechnology, biology, and medicine · 2024 · Journal Article
Wei X, Zhao G, Chen N, Xu X, et al.
ACS omega · 2024 · Journal Article
Ching PCO, Chen FH, Lin IH, Tran DT, et al.
Journal of medical cases · 2024 · Case Reports
Hung TD, Ha PVT, Chien DV
Journal of community hospital internal medicine perspectives · 2023 · Case Reports
Tran DH, Verceles AC, Marciniak ET
Cureus · 2022 · Case Reports
Tran DH, Jaggon KS, Mikdashi J, Chow RD, et al.
Scientific reports · 2022 · Journal Article
Tran DH, Hoshino H, Matsuyama Y
Modern rheumatology · 2021 · Journal Article
Tran DH, Hoshino H, Matsuyama Y
Aging clinical and experimental research · 2020 · Journal Article
Tran DH, Hoshino H, Togawa D, Matsuyama Y
The International journal of oral & maxillofacial implants · 2016 · Comparative Study
Tran DT, Gay IC, Diaz-Rodriguez J, Parthasarathy K, et al.
Journal of community health · 2010 · Journal Article
Banerjee D, Perry M, Tran D, Arafat R
The American journal of case reports · 2019 · Case Reports
Okajima K, Posas-Mendoza T, Tran DD, Hong RA
Arthritis and rheumatism · 2005 · Clinical Trial
Ramanan AV, Campbell-Webster N, Ota S, Parker S, et al.
Dental and medical problems · 2023 · Meta-Analysis
Tran DQ, Vu CTQ, Phan QN, Nguyen CTM
Genes · 2022 · Journal Article
Pham T, Nguyen QT, Tran DM, Nguyen H, et al.
Journal of clinical laboratory analysis · 2022 · Journal Article
Nguyen Duy T, Dao Bui Quy Q, Ho Viet Le D, Le Ha K, et al.
Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025 · Journal Article
Tran DH, Narla R, Wojtowicz M, Spoutz P, et al.
Dental and medical problems · 2023 · Meta-Analysis
Tran DQ, Vu CTQ, Phan QN, Nguyen CTM
Dental and medical problems · 2023 · Meta-Analysis
Tran DQ, Vu CTQ, Phan QN, Nguyen CTM
Scientific reports · 2023 · Journal Article
Tanaka T, Nakamura H, Tran DT, Warner BM, et al.
Ocular immunology and inflammation · 2025 · Journal Article
Tran D, Rogers S, Lim LL